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Background: In Italy the prevalence of genital warts in women (15–64 years) is approximately 0.6% with an
incidence of 0.4% per year. Treatments for GW are usually long, with moderate success and high costs. The aim of
the study was to evaluate the diagnostic-therapeutic pathway, duration and setting of treatment, costs of episodes
of condyloma in a population attending a regional STI clinic in Piedmont.
Methods: This was a retrospective observational study conducted using medical records of outpatients who first
visited the STI Clinic of San Lazzaro Dermatological Hospital in 2008. The patients’ medical histories were analysed
for episodes that occurred and were cleared in 18 months following the initial visit. Data on screening methods for
STIs, type of diagnosis for condyloma, treatment type, treatment setting, and anatomic lesion site were obtained
from medical records. The costs were calculated for each episode.
Results: A total of 450 episodes were analysed (297 men,153 women). The most frequently affected anatomic site
was the genital area (74%) in both genders. With regard to treatment setting, 78.44% of patients received
outpatient treatment at the STI clinic, 4% were treated at home, and 0.22% were hospitalised; 11.11% were treated
in multiple settings. The mean number of treatments per episode was 2.03; although many patients received only 1
treatment (n = 207, 46%), exspecially cryotherapy or diathermy coagulation (64.73% versus 28.02% of episodes,
respectively). The mean episode duration was 80.74 days. The mean cost (in 2011 euros) for an episode was
€158.46 ± 257.77; the mean costswere €79.13 ± 57.40 for diagnosis and €79.33 ± 233.60 for treatment. The mean
cost for treatment in a STI-Clinic setting was €111.39 ± 76.72, that for home treatment was €160.88 ± 95.69, and that
for hospital care was €2825.94.
Conclusions: The treatment of and associated costs for genital warts are significant. Several factors affect the
cost, and internal STI clinic protocols, such as the 6 month window used to consider a recurrence or new
diagnosis, create bias. Nonetheless, our findings how costs similar to those reported in the international
literature and should be considered when deciding on which HPV vaccination programs should be provided
by the public health system.
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According to the Italian network of sexually transmitted
infection (STI) sentinel clinic surveillance system, genital
warts (GW), along with human papillomavirus (HPV) in-
fections, are the most frequently occurring STI in Italy,
representing 35.9% of STI diagnoses [1,2].
Genital warts are caused by HPV types 6 and 11, which
are responsible for more than 90% of cases. In Italy, it has
been estimated that the prevalence of genital warts in
women between 15 and 64 years of age is approxi-
mately0.6%, with an incidence of approximately 0.4% per
year [3]. The international literature estimates a similar
range of 0.2%-0.7% in males and females [4-6]. In Europe,
recent data show that every year, there are almost 600,000
new cases of genital warts, and these cases occur equally
in both men and women.
Treatments for GW are usually long, with moderate suc-
cess and high costs. The only effective prevention is vac-
cine protection against HPV types 6 and 11. Currently, two
HPV vaccines are commercially available: Gardasil (Merck
Frosst, Quebec, Canada) and Cervarix (GlaxoSmithKline,
Brentford, UK). Both vaccines are highly effective in pro-
tecting against cervical cancer. However, only the quadriva-
lent vaccine has been shown to be effective against genital
warts (GW) [7,8] in almost 100% of cases. The effective-
ness of the quadrivalent vaccine has been demonstrated by
real-life data in Australia, where GW incidence was re-
duced by nearly 94% among the vaccinated population in
the 4 years after vaccination began [9].
In Italy, an anti-HPV vaccination campaign was intro-
duced in 2007, mainly targeted against cervical cancer,
among 12 year old girls. At the time, the high burden of
disease (cervical cancer) in women in Italy and the high
efficacy of the vaccine and safety data supported this
decision. In addition, at that time, little was known by the
scientific community in Italy concerning other HPV-re-
lated cancers and genital warts, and most official bodies
recommended vaccination campaigns to primarly to target
cervical carcinoma. Protecting against HPV types 16/18
(included in both vaccines) meant an estimated 70% re-
duction in cervical cancers in the years to come.
Genital warts are not a mandatory reportable disease in
Italy. Therefore, there is a lack of registries, making it diffi-
cult to calculate the real impact of this disease. The only
available data comes from the sentinel surveillance net-
work of sexually transmitted infection clinics and from
“ad hoc” studies. The Italian surveillance system for STI
was established in 1991 [10,11] and involves collaboration
with a network of public clinical centres that specialise in
the diagnosis and treatment of STIs throught the country.
Currently, there are 12 regional centres that collect data
from a network of clinical centres that share diagnostic
and therapeutic protocols. GW patients are difficult to fol-
low; they do not tend to visit any specific specialist orclinic. STI clinics see only a small number of referred pa-
tients from other specialists or general practitioners. Most
patients are treated outside of STI clinics, some as outpa-
tients and some as inpatients, and treatment procedures
vary greatly from medical to surgical treatments. Men
tend to go to general practitionaires, urologists, andro-
logists or dermatologists. In contrast, women go mainly to
gynaecologists or dermatologists. Patients usually require
multiple visits - one study estimated an average of 5.7
visits for men and 6.3 visits for women [12] - and costs
are usually high and highly variable. In Italy, costs range
from 250 to 830 euros 5,6 [13].
Italy not only lacks definitive epidemiological data, which
is mostly underestimated and biased by several factors,
but it lacks estimates of the economic burden of disease.
The aim of this study is to evaluate the diagnostic-the-
rapeutic pathway and the costs of GW in one of the STI
clinics situated in the region of Piedmont, Italy. This re-
gion has a population of 4 million, and more than 50% of
the cases reported by the STI clinic regional surveillance
network visit this particular clinic. STI clinic management
in the Piedmont region follows these principles: service is
accessible to all patients, services are offered free of charge,
privacy of patients is guaranteed, and data collection is to-
tally anonymous. This study aims to give an estimate of
the cost of genital warts for the Italian health system.
Methods
We carried out a retrospective analysis of outpatients who
had their first visited the STI Clinic of San Lazzaro Der-
matological Hospital, San Giovanni Battista Teaching
Hospital, Turin in 2008. The patients’ medical histories
for the 18 months following the initial visit were noted on
their medical records.
An episode was defined by a panel of dermatologists as
“any infection from the initial diagnosis to the clearance
occurring during a period of 18 months”.
Clearance was defined as “the patient being free of dis-
ease or not coming back to the hospital for follow up-
visits for 6 months after the last treatment”.
Therefore, an episode could include the occurrence of
new lesions, the recurrence of previously treated lesions
or new sites of infection within less than 6 months of last
treatment.
The study focused only on the episodes; patients in con-
comitant treatment for other STIs were excluded, with the
exception of HIV - positive patients.
The study protocol was approved by the Institutional
Ethics Committee of San Giovanni Battista Teaching Hos-
pital (Protocol 00009624 – 08 February 2010).
According to the clinical pathway of GW management
(Figure 1), we evaluated the methods of screening, the
types of exams for diagnosis, and the types and numbers
of treatments for each episode.
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Figure 1 Flow diagram of clinical pathway of genital warts management.
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the treatment setting. Anatomic sites of condyloma were
classified as follows : genital (cervix, vagina, urethra, penis,
or scrotum); anal (anus or perianal tissue); extragenital
(groin, perineum or pubes); and multiple (any combin-
ation of at least two of the preceding). Treatment settings
included the STI outpatient clinic, the home, the hospital
or different combinations thereof.
The patients, on the basis of treatment numbers, were
divided into seven classes: class 0 for patients who had
undergone screening and diagnosis but not treatment; 1
for patients who had undergone screening and diagno-
sis and received treatment in a single visit; and 2, 3, 4, 5,
and >5 for patients who had undergone screening and
diagnosis and at least two treatments of the same or a dif-
ferent type.
The medical records were also searched for the mean
duration of each episode of condyloma.
The cost analysis was performed from the perspective of
the third-party payer (region of Piedmont) according to
the breakdown shown in Table 1:– the data on the hospitalization cost were taken from
the 2011 hospitalization rates for Piedmont: DRG
267 with principal diagnosis code 07811 and
intervention code 4904;
– the data on outpatient services were taken from the
2011 outpatient rates for Piedmont;
– the reference for the costs of pharmacotherapy was
made to the pharmacy retail price.
To calculate the mean costs we evaluated the cost of
type of exams for screening and diagnosis and of type and
number of treatment for each episode.
The costs for the various components, screening, diag-
nosis and treatment were stratified by patient sex and site
of infection; the costs for diagnosis and treatment were
also stratified by the setting of service delivery.
Statistical analysis
All analyses were carried out using Stata 11 Version.
The quantitative variables were synthesized with the
mean ± standard deviation (SD) and the median and inter-
Table 1 Cost breakdown
Resource Unit costs (€)
Blood chemistry screening for:
HIV (HIV-1 and HIV-2 antibody antigen) €10.35
HBV (HBc antibodies) €10.40
Syphilis (anti-treponema antibodies) €7.80
Cervical swab for gonorrhea (detection by PCR assay) €180.05
Cervical swab for chlamydia (detection by PCR assay) €180.05
First jet urine (DNA amplification by PCR assay) €180.05
Diagnosis*
First dermatological examination €30.00
Anoscopy €32.50
Biopsy €19.85
Proctological examination €21.45
Oncological examination €20.00
Second dermatological examination €20.00
STI Clinic Treatments*
Cryotherapy €18.35
Diathermy coagulation €18.35
Surgical shave €40.65
Home Treatments (pharmacotherapy)**
Imiquimod 5% (Aldara) € 76.56
Podofillotox (Wartec) €28.40
Hospitalization treatments (DRG 267)*** €1371.72
* The data for costs were taken from the current rates for outpatient services
(2011 - Piedmont Region).
** Pharmacy retail price.
*** Cost were taken from the 2011 hospitalization rates for Piedmont: DRG 267
with principal diagnosis code 07811 and intervention code 4904.
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and Standard Deviation (SD).
We examined: a) Anatomic site, duration and setting of
treatment; b) Cost of condyloma episodes. To evaluate the
possible associations between outcomes and categorical
covariates, the Chi-square test were used. T-student test
were used to compare continuous variables. Significance
threshold was set at p < 0.05 (2-tailed) for all analyses.
Results and discussion
The medical records of 502 outpatients (325 males, mean
age 34.27 ± 11.62 years; 177 females, mean age 30.92 ±
10.98 years) were reviewed. At the end of the 18-month
observation period, 52 patients were still under therapy
and were therefore not included in the final analysis.
There were 450 episodes of condyloma infection included
in the study (89.64%).
Anatomic site
The most frequently affected anatomic site was the genital
area (74%), followed by the anus (12.67%) and multiplesites (11.33%). The least frequently affected site was the
extragenital area (2%) (Figure 2).
The distribution of episodes by anatomic site differed
between males and females (P < 0.001): the genital area
was the most affected site (83.16% and 56.21% in males
and females, respectively); the extragenital area was the
least affected site (2.69% and 0.65% in males and females,
respectively); the anus was more often affected than mul-
tiple sites in males (10.77% versus 3.37%), whereas the op-
posite was observed in females (16.34% versus 26.80%)
(Figure 2).
Treatments
With regard to treatment setting, 78.44% of patients re-
ceived treatment at the STI clinic, 4% were treated at
home, and 0.22% were hospitalised; 11.11% we treated in
several different settings (9.33% at the STI clinic and at
home; 1.11% at the STI clinic and in the hospital; 0.22% at
home and in the hospital; and 0.44% at home, at the STI
clinic and in the hospital); 28 (6.22%) received no treat-
ment because of dropout. The mean number of treat-
ments per episode was 2.03 (Table 2).
Forty-six percent of patients received 1 treatment (n =
207); the number of patients decreased as the number of
treatments increased up to 5 treatments, after which the
number of treatments increased in parallel with the number
of patients who had received more than 5 treatments
(3.33%) (Table 2). This trend was similar for both sexes,
and according to anatomic site, except for the anal area
(Table 2). There was no statistically significant difference in
the mean number of treatments between males and females
(P = 0.43) or in the anatomic site of condyloma (P = 0.23).
The most frequent type of therapy was 1 treatment with
cryotherapy or diathermy coagulation (64.73% versus
28.02% of episodes); pharmacotherapy was much less fre-
quent (approxximately 6.28% of patients).
In patients who received 2 treatments, the majority
(54.55%) underwent 2 sessions of cryotherapy, followed by
a combination of diathermy coagulation and cryotherapy
(14.14%). Among patients who received between 3 and 4
treatments, most received multiple treatments of cryother-
apy alone. No predominant sequence of treatment was ob-
served in patients who received more than 4 treatments.
Analysis of the number of treatments per setting showed
that the mean number was higher when patients were
treated in a combination of different settings, except for
the hospital and home combination, as this combination
involved only 1 patient. The lowest number of treatments
was observed in patients treated at home (Table 2). There
was a statistically significant association between the num-
ber of treatments and treatment setting (P < 0.001).
The mean episode duration was 80.74 days. No statisti-
cally significant difference in mean duration was observed
between males and females (P = 0.363) or among anatomic
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Genital Anal Extragenital Multiple
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Figure 2 Percent of episodes of infection with condyloma in males and females stratified by site of infection.
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cant difference in mean duration according to the setting
(P < 0.001): the mean duration was longer for patients
treated with a combination of different treatment settings
(Table 2).Cost of condyloma episodes
The mean cost (diagnosis and treatment) for an episode of
condyloma was €158.46 ± 257.77: the mean cost of diag-
nosis was €79.13 ± 57.39, and that of treatment was
€79.33 ± 233.60.
The mean costs of screening, diagnosis and treatment of
a condyloma episode, stratified according to sex and site
of infection, are shown in Figure 3.
There was a statistically significant difference in the
mean cost between females and males (€161.35 ± 267.30
versus €156.97 ± 253.17) (P = 0.008) and in the mean cost
according to site of infection (P = 0.0001): anal condy-
lomata were the most expensive, and extragenital sites of
infection the least expensive.
When the cost of screening (€152.58 ± 170.46) was
added to the cost of diagnosis and treatment, the mean
cost per episode was €311.04 ± 310.54: the mean cost of
screening was €386.30 ± 29.11 for females and €32.19 ±
29.37 for males.
The mean cost (diagnosis and treatment) in the STI-
Clinic setting was €111.39 ± 76.72; the costs for home
(€160.88 ± 95.69) and hospital care (€2825.94) were
higher. The mean cost for patients treated in a combin-
ation of different settings was progressively higher startingwith STI clinic and home (€273.37 ± 146.40), then STI
clinic and hospital (€1565.25 ± 52.43), and finally hospital
and home (€1886.36) (Table 3).Conclusions
The aim of this study was to examine the diagnostic-
therapeutic pathways of a cohort of patients with con-
dyloma and to determine the cost for a single episode.
This approach distinguishes our study from others that
investigated either the total cost of infection with con-
dyloma over one or more years or the mean annual
cost of condyloma diagnosis and treatment in cases
that had or had not yet cleared [12,14-18]. During the
18-month observation period, we noted 450 episodes
(89.64% of medical records reviewed). The mean dur-
ation of an episode was 80.74 days; this finding is in
line with previous observations by Hoy (95.4 days) and
Marra (69.3 days) [19,20].
Similar to a study by Insinga [21] but different from
other studies [19,20] our findings showed that the mean
duration of an episode of infection with condyloma was
longer for females than for males. This difference might
have been observed because might have been observed be-
cause women in Italy usually seek care from their private
gynaecologists and visit an STI clinic only in more compli-
cated cases.
The mean number of treatments was similar to that
reported elsewhere: 2.4 by Marra [20] and 2.2 by Hoy [19].
The mean number of treatments was slightly higher for
males than for females; our range (2,05 for males versus
Table 2 Episodes classified by number of treatments and duration of episodes and stratified by sex, site of infection, and care setting
TOTAL 0 Treatment N.
episodes (%)
1 Treatment N.
episodes (%)
2 Treatment N.
episodes (%)
3 Treatment N.
episodes (%)
4 Treatment N.
episodes (%)
5 Treatment N.
episodes (%)
>5 Treatment
N. episodes (%)
Mean no. of
treatments (SD)
Mean duration of
episode (days) (SD)
Total-N. = 450
(100%)
450 (100) 28 (6.22) 207 (46.0) 99 (22) 56 (12.44) 31 (6.89) 14 (3.11) 15 (3.33) 2.03 (1.34) 80.74 (92.13)
Gender
Men 297 (100) 18 (6.06) 130 (43.77) 70 (23.57) 41 (13.80) 21 (7.07) 8 (2.69) 9 (3.03) 2.05 (1.30) 79.79 (94.74)
Women 153 (100) 10 (6.54) 77 (50.33) 29 (18.95) 15 (9.80) 10 (6.54) 6 (3.92) 6 (3.92) 2.00 (1.41) 82.60 (87.14)
Site
Genital 333 (100) 17 (5.11) 161 (48.35) 73 (21.92) 41 (12.31) 23 (6.91) 7 (2.10) 11 (3.30) 2.22 (1.68) 72.78 (88.30)
Anal 57 (100) 8 (14.04) 19 (33.33) 15 (26.32) 7 (12.27) 3 (5.26) 4 (7.02) 1 (1.75) 2.87 (2.09) 125.14 (108.38)
Extragenital 9 (100) 1 (11.11) 5 (55.56) 1 (11.11) 1 (11.11) 1 (11.11) 0 (0) 0 (0) 2.23 (2.06) 66.33 (95.40)
Multiple 51 (100) 2 (3.92) 22 (43.14) 10 (19.61) 7 (13.73) 4 (7.84) 3 (5.88) 3 (5.88) 2.47 (1.78) 85.55 (84.30)
Setting*
STI Clinic 353 (100) 194 (54.96) 81 (22.95) 39 (11.05) 22 (6.23) 9 (2.55) 8 (2.27) 1.85 (1.22) 75.20 (86.0)
Home 18 (100) 13 (72.22) 4 (22.22) 0 (0) 1 (5.56) 0 (0) 0 (0) 1.39 (0.78) 31.11 (47.26)
Hospital 1 (100) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 2.00 (0) 9.00 (0)
STI Clinic and
Home
42 (100) 0 (0) 11 (26.19) 14 (33.33) 6 (14.29) 4 (9.52) 7 (16.67) 3.57 (1.42) 156.26 (117.57)
STI Clinic and
Hospital
5 (100) 0 (0) 2 (40.0) 2 (40.0) 1 (20.0) 0 (0) 0 (0) 280 (0.84) 150.00 (80.62)
Hospital and
Home
1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 5.00 (0) 288.00 (21.21)
STI Clinic and
Hospital and
Home
2 (100) 0 (0) 0 (0) 1 (50.0) 1 (50.0) 0 (0) 0 (0) 3.50 (0.71) 259.00 (21.21)
SD, Standard Deviation; IQR, Interquartile range.
* only patient with treatment.
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(2.5 versus 1.9) [19].
There was a marked predominance of monotherapy,
with cryotherapy being the treatment most often utilised.
Differing from the findings reported by Van Der Meijden
[14] our study revealed a low prescription rate for
podophyline (Wartec).
The majority of episodes were treated in a single setting,
the STI clinic, where most infections with condyloma
were cleared with a single treatment.
Treatment with hospitalisation occurred in 1.2% of epi-
sodes, significantly fewer than that reported by Merito
(12.6%) [15] because most of the episodes in our study
were treated by cryotherapy delivered in the STI clinic.
Home treatment was also far less frequent in our study
than in that by Merito (14% versus 36.5%) [15] as there
was a low level of podophyline prescription in our study.Table 3 Mean cost (in 2011 Euros) of diagnosis and treatmen
SETTING Diagnosisb (SD)
STI Clinic 75,06 (54,21)
Home 57,22 (36,29)
Hospital 82,50 (−)
STI Clinic and Home 119,07 (67,84)
STI Clinic and Hospital 160,50 (53,19)
Hospital and Home 135,00 (−)
STI Clinic and Hospital and Home 241,25 (93,69)
b Only patients who received treatment (N.422).
SD, Standard Deviation.The mean cost of diagnosis and treatment per episode
was €158.46, which is fairly similar to that reported by
Marra (€133.68 at 2006 exchange rates) 20 and Desai
(€130.20 at 2011 exchange rates) [13] but far less than
those reported by Hoy (€520.14 at 2004 exchange rates)
[19] or Insinga (€472.07 at 2000 exchange rates) [21] The
likely reason for this difference is that the latter two stud-
ies refer to private health care plans that differ substan-
tially from the Italian national health system in the
delivery of services, costs of services and type of treatment
given. Insinga [21] for example, reported that approxi-
mately 40% of patients received drug therapy, compared
to 9.6% of those in our cohort, and that the mean cost of a
visit was €118, compared to €30.00 in our study. Costs of
care of GWs were reported from the United Kingdom (€
363.93 for males and € 346.31 for females) [12] and the
Netherlands (€ 221.34 for males and € 292.29 for females)t of a condyloma episode stratified by care setting
Treatmentb (SD) Total Diagnosis + Treatmentb (SD)
36,33 (29,61) 111,39 (76,72)
103,66 (61,98) 160,88 (95,69)
2.743,44 (−) 2825,94 (−)
154,31 (86,60) 273,37 (146,40)
1.404,75 (15,35) 1.565,25 (52,43)
1751,36 (−) 1.886,36 (−)
1.504,91 (54,14) 1.746,16 (147,83)
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342.40) [5] in 2005 and from Ireland (€ 335) [18] in 2007.
Comparisons with our cost of management per episode
are not straightforward because of differences in target
and setting studied and in episode definitions.
The mean cost per episode of infection with condyloma
was higher for females than for males, which is in line
with previous studies of health care systems similar to that
of Italy [20,21] but contrasts with studies conducted in the
United States, where the mean cost per episode was found
to be higher for males than for females. One of the factors
that drives up the cost per episode in females is the cost
of diagnosis, most likely because more females than males
present with anal condyloma (16.34% versus 10.77%) and
multiple sites of infection (26.80% versus 3.37%), which re-
quire more costly procedures such as anoscopy. Further-
more, anal warts incur higher costs because they require
more treatments and take longer to clear. Episodes of in-
fection treated at an STI clinic are the least expensive,
whereas those treated in the hospital are the most expen-
sive. This differenceis confirmed by a previous study in
Italy in which a higher number of hospitalisations in-
creased the mean annual cost per patient [15].
Our study has several limitations. The first limitation is
that the study was conducted at only one of the region’s
STI centres, although this centre receveid more than 50%
of the condyloma infections. The second limitation is that
our study enrolled only cases diagnosed by the public
health system, and could be missing patients who sought
diagnosis and treatment from private providers. As shown
by the data reported by Insinga [21] the number of pa-
tients who visited private providers may shift the eco-
nomic burden of infection with condyloma.
The third limitation is that our study focused only on ep-
isodes that had cleared during the 18-month observation
period. Having a longer observation period would permit
the enrolment of patients with episodes of longer duration,
which would consequently increase the mean cost of care.
In conclusion, our study shows that the treatment of
genital warts and the associated costs are significant.
Among other factors, this burden and cost should be con-
sidered when deciding on which HPV vaccination pro-
grams should be provided by public health systems. Due
to the limitations listed above, our results are likely to
have underestimated the number of cases and economic
burden of condyloma.
Highlights
We performed a retrospective analysis of medical re-
cords of outpatients with condyloma and obtained the
following results:
 For each episode, the mean duration was 80.74 days
and the mean number of treatments was 2.34. The most frequent treatment setting was STI clinic.
 The mean cost for an episode of condyloma was
€158.46.
 The mean costs of diagnosis and treatment were
€79.13 and €84.59, respectively.
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